pf-184563 pf-184563 pf-184563 is a potent, selective non-peptidic antagonist of the v1a receptor. the compound was discovered by pfizer in its sandwich, kent research center, as a potential treatment for dysmenorrhoea, an indication for which v1a antagonists have shown efficacy. pf-184563clinical dataatc codenonepharmacokinetic databioavailability34%protein binding69%elimination half-life1.8hidentifiers iupac name 8-chloro-5-methyl-1-(3,4,5,6-tetrahydro-2h-bipyridinyl-4-yl)-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzoazulene cas number748806-39-5 ychemspider9412479 nchemblchembl1837037 nchemical and physical dataformulac21h23cln6molar mass394.91 g·mol−13d model (jsmol)interactive image smiles cn1cc2=c(c=cc(=c2)cl)n3c(=nn=c3c4ccn(cc4)c5=cc=cc=n5)c1 inchi inchi=1s/c21h23cln6/c1-26-13-16-12-17(22)5-6-18(16)28-20(14-26)24-25-21(28)15-7-10-27(11-8-15)19-4-2-3-9-23-19/h2-6,9,12,15h,7-8,10-11,13-14h2,1h3 nkey:lxhaznjvvvbjif-uhfffaoysa-n n ny (what is this?) (verify)